{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T11:55:13Z","timestamp":1782129313183,"version":"3.54.5"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T00:00:00Z","timestamp":1755993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T00:00:00Z","timestamp":1755993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02994-w","type":"journal-article","created":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T12:31:51Z","timestamp":1756038711000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Drug repurposing in oncology: a path beyond the bottleneck"],"prefix":"10.1007","volume":"42","author":[{"given":"Neha","family":"Sajwani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. P.","family":"Suchitha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. S.","family":"Keshava Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shobha","family":"Dagamajalu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,24]]},"reference":[{"issue":"3","key":"2994_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"2994_CR2","doi-asserted-by":"publisher","first-page":"1201419","DOI":"10.3389\/fddsv.2023.1201419","volume":"3","author":"N Singh","year":"2023","unstructured":"Singh N, Vayer P, Tanwar S, Poyet JL, Tsaioun K, Villoutreix BO. Drug discovery and development: introduction to the general public and patient groups. Front Drug Discov. 2023;3:1201419.","journal-title":"Front Drug Discov"},{"issue":"4","key":"2994_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/jpm10040200","volume":"10","author":"M \u00c1valos-Moreno","year":"2020","unstructured":"\u00c1valos-Moreno M, L\u00f3pez-Tejada A, Blaya-C\u00e1novas JL, Cara-Lupia\u00f1ez FE, Gonz\u00e1lez-Gonz\u00e1lez A, Lorente JA, S\u00e1nchez-Rovira P, Granados-Principal S. Drug repurposing for triple-negative breast cancer. J Pers Med. 2020;10(4): 200.","journal-title":"J Pers Med"},{"key":"2994_CR4","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.conctc.2018.08.001","volume":"11","author":"DB Fogel","year":"2018","unstructured":"Fogel DB. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. Contemp Clin Trials Commun. 2018;11:156\u201364.","journal-title":"Contemp Clin Trials Commun"},{"issue":"7","key":"2994_CR5","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/nrd3480","volume":"10","author":"DC Swinney","year":"2011","unstructured":"Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov. 2011;10(7):507\u201319.","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"2994_CR6","first-page":"14","volume":"48","author":"O Hilas","year":"2023","unstructured":"Hilas O. Trends in FDA-approved cancer therapies. US Pharm Pharm Resour Clin Excell. 2023;48(10):14.","journal-title":"US Pharm Pharm Resour Clin Excell"},{"key":"2994_CR7","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.phrs.2017.07.013","volume":"124","author":"L Sleire","year":"2017","unstructured":"Sleire L, F\u00f8rde HE, Netland IA, Leiss L, Skeie BS, Enger P\u00d8. Drug repurposing in cancer. Pharmacol Res. 2017;124:74\u201391.","journal-title":"Pharmacol Res"},{"key":"2994_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111638","volume":"141","author":"HV Sonaye","year":"2021","unstructured":"Sonaye HV, Sheikh RY, Doifode CA. Drug repurposing: iron in the fire for older drugs. Biomed Pharmacother. 2021;141: 111638.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"2994_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, Doig A, Guilliams T, Latimer J, McNamee C, Norris A, Sanseau P, Cavalla D, Pirmohamed M. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41\u201358.","journal-title":"Nat Rev Drug Discov"},{"issue":"2","key":"2994_CR10","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.apsb.2021.09.006","volume":"12","author":"L Fu","year":"2022","unstructured":"Fu L, Jin W, Zhang J, Zhu L, Lu J, Zhen Y, Zhang L, Ouyang L, Liu B, Yu H. Repurposing non-oncology small-molecule drugs to improve cancer therapy: current situation and future directions. Acta Pharm Sin B. 2022;12(2):532\u201357.","journal-title":"Acta Pharm Sin B"},{"issue":"6","key":"2994_CR11","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1476-5381.2010.01127.x","volume":"162","author":"JP Hughes","year":"2011","unstructured":"Hughes JP, Rees S, Kalindjian SB, Philpott KL. Principles of early drug discovery. Br J Pharmacol. 2011;162(6):1239\u201349.","journal-title":"Br J Pharmacol"},{"key":"2994_CR12","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.12662.1","volume":"6","author":"M Powers","year":"2017","unstructured":"Powers M, Greven M, Kleinman R, Nguyen QD, Do D. Recent advances in the management and understanding of diabetic retinopathy. F1000Res. 2017;6: 2063.","journal-title":"F1000Res"},{"issue":"4","key":"2994_CR13","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.tips.2021.01.003","volume":"42","author":"HI Roessler","year":"2021","unstructured":"Roessler HI, Knoers NVAM, van Haelst MM, van Haaften G. Drug repurposing for rare diseases. Trends Pharmacol Sci. 2021;42(4):255\u201367.","journal-title":"Trends Pharmacol Sci"},{"key":"2994_CR14","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2147\/DDDT.S46289","volume":"7","author":"M Allarakhia","year":"2013","unstructured":"Allarakhia M. Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases. Drug Des Dev Ther. 2013;7:753\u201366.","journal-title":"Drug Des Dev Ther"},{"key":"2994_CR15","doi-asserted-by":"crossref","unstructured":"Rudrapal M, Khairnar SJ, Jadhav AG. Drug repurposing (DR): an emerging approach in drug discovery. In: Drug repurposing\u2014hypothesis, molecular aspects and therapeutic applications. London: IntechOpen Limited; 2020.","DOI":"10.5772\/intechopen.93193"},{"issue":"9","key":"2994_CR16","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s11094-022-02778-w","volume":"56","author":"N Rao","year":"2022","unstructured":"Rao N, Poojari T, Poojary C, Sande R, Sawant S. Drug repurposing: a shortcut to new biological entities. Pharm Chem J. 2022;56(9):1203\u201314.","journal-title":"Pharm Chem J"},{"issue":"3","key":"2994_CR17","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/wsbm.1337","volume":"8","author":"RA Hodos","year":"2016","unstructured":"Hodos RA, Kidd BA, Shameer K, Readhead BP, Dudley JT. In silico methods for drug repurposing and pharmacology. Wiley Interdiscip Rev Syst Biol Med. 2016;8(3):186\u2013210.","journal-title":"Wiley Interdiscip Rev Syst Biol Med"},{"issue":"1","key":"2994_CR18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41392-020-00213-8","volume":"5","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Zhou L, Xie N, Nice EC, Zhang T, Cui Y, Huang C. Overcoming cancer therapeutic bottleneck by drug repurposing. Signal Transduct Target Ther. 2020;5(1):113.","journal-title":"Signal Transduct Target Ther"},{"key":"2994_CR19","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.3389\/fonc.2019.01503","volume":"9","author":"L Li","year":"2020","unstructured":"Li L, Hu M, Wang T, Chen H, Xu L. Repositioning aspirin to treat lung and breast cancers and overcome acquired resistance to targeted therapy. Front Oncol. 2020;9:1503.","journal-title":"Front Oncol"},{"issue":"6","key":"2994_CR20","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1001\/jama.2009.1112","volume":"302","author":"AT Chan","year":"2009","unstructured":"Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009;302(6):649\u201358.","journal-title":"JAMA"},{"issue":"2","key":"2994_CR21","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.cmet.2016.12.009","volume":"25","author":"JJ Howell","year":"2017","unstructured":"Howell JJ, Hellberg K, Turner M, Talbott G, Kolar MJ, Ross DS, Hoxhaj G, Saghatelian A, Shaw RJ, Manning BD. Metformin inhibits hepatic mTORC1 signaling via dose-dependent mechanisms involving AMPK and the TSC complex. Cell Metab. 2017;25(2):463\u201371.","journal-title":"Cell Metab"},{"issue":"5","key":"2994_CR22","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.cmet.2010.03.014","volume":"11","author":"A Kalender","year":"2010","unstructured":"Kalender A, Selvaraj A, Kim SY, Gulati P, Br\u00fbl\u00e9 S, Viollet B, Kemp BE, Bardeesy N, Dennis P, Schlager JJ, Marette A, Kozma SC, Thomas G. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 2010;11(5):390\u2013401.","journal-title":"Cell Metab"},{"issue":"10","key":"2994_CR23","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1080\/15384101.2020.1743911","volume":"19","author":"Z Zheng","year":"2020","unstructured":"Zheng Z, Bian Y, Zhang Y, Ren G, Li G. Metformin activates AMPK\/SIRT1\/NF-\u03baB pathway and induces mitochondrial dysfunction to drive caspase3\/GSDME-mediated cancer cell pyroptosis. Cell Cycle. 2020;19(10):1089\u2013104.","journal-title":"Cell Cycle"},{"issue":"1","key":"2994_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-021-02012-7","volume":"40","author":"J Yang","year":"2021","unstructured":"Yang J, Zhou Y, Xie S, Wang J, Li Z, Chen L, Mao M, Chen C, Huang A, Chen Y, Zhang X, Khan NUH, Wang L, Zhou J. Metformin induces ferroptosis by inhibiting UFMylation of SLC7A11 in breast cancer. J Exp Clin Cancer Res. 2021;40(1): 206.","journal-title":"J Exp Clin Cancer Res"},{"issue":"7","key":"2994_CR25","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s12032-023-02057-y","volume":"40","author":"S Verma","year":"2023","unstructured":"Verma S, Chitikela S, Singh V, et al. A phase II study of metformin plus pemetrexed and carboplatin in patients with non-squamous non-small cell lung cancer (METALUNG). Med Oncol. 2023;40(7):192. https:\/\/doi.org\/10.1007\/s12032-023-02057-y.","journal-title":"Med Oncol"},{"issue":"6","key":"2994_CR26","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.3390\/cancers14061504","volume":"14","author":"MP Udumula","year":"2022","unstructured":"Udumula MP, Poisson LM, Dutta I, et al. Divergent metabolic effects of metformin merge to enhance eicosapentaenoic acid metabolism and inhibit ovarian cancer in vivo. Cancers (Basel). 2022;14(6):1504. https:\/\/doi.org\/10.3390\/cancers14061504.","journal-title":"Cancers (Basel)."},{"issue":"27","key":"2994_CR27","doi-asserted-by":"publisher","first-page":"23548","DOI":"10.18632\/oncotarget.4556","volume":"6","author":"LM Litchfield","year":"2015","unstructured":"Litchfield LM, Mukherjee A, Eckert MA, et al. Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer. Oncotarget. 2015;6(27):23548\u201360. https:\/\/doi.org\/10.18632\/oncotarget.4556.","journal-title":"Oncotarget"},{"issue":"6","key":"2994_CR28","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s10637-017-0511-7","volume":"35","author":"AB Parikh","year":"2017","unstructured":"Parikh AB, Kozuch P, Rohs N, Becker DJ, Levy BP. Metformin as a repurposed therapy in advanced non-small cell lung cancer (NSCLC): results of a phase II trial. Investig N Drugs. 2017;35(6):813\u20139. https:\/\/doi.org\/10.1007\/s10637-017-0511-7.","journal-title":"Investig N Drugs"},{"issue":"9","key":"2994_CR29","doi-asserted-by":"publisher","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","volume":"91","author":"RJ D'Amato","year":"1994","unstructured":"D\u2019Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91(9):4082\u20135. https:\/\/doi.org\/10.1073\/pnas.91.9.4082.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2994_CR30","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1200\/JCO.2003.08.045","volume":"21","author":"HA Fine","year":"2003","unstructured":"Fine HA, Wen PY, Maher EA, et al. Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas. J Clin Oncol. 2003;21(12):2299\u2013304. https:\/\/doi.org\/10.1200\/JCO.2003.08.045.","journal-title":"J Clin Oncol"},{"issue":"10","key":"2994_CR31","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1056\/NEJMoa053583","volume":"354","author":"B Barlogie","year":"2006","unstructured":"Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354(10):1021\u201330. https:\/\/doi.org\/10.1056\/NEJMoa053583.","journal-title":"N Engl J Med"},{"issue":"11","key":"2994_CR32","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.3109\/13880209.2014.892513","volume":"52","author":"OD I\u015feri","year":"2014","unstructured":"I\u015feri OD, Sahin FI, Terzi YK, Yurtcu E, Erdem SR, Sarialioglu F. Beta-adrenoreceptor antagonists reduce cancer cell proliferation, invasion, and migration. Pharm Biol. 2014;52(11):1374\u201381.","journal-title":"Pharm Biol"},{"issue":"1","key":"2994_CR33","doi-asserted-by":"publisher","first-page":"7050","DOI":"10.1038\/s41598-018-25340-9","volume":"8","author":"L Broh\u00e9e","year":"2018","unstructured":"Broh\u00e9e L, Peulen O, Nusgens B, Castronovo V, Thiry M, Colige AC, Deroanne CF. Propranolol sensitizes prostate cancer cells to glucose metabolism inhibition and prevents cancer progression. Sci Rep. 2018;8(1):7050.","journal-title":"Sci Rep"},{"issue":"3","key":"2994_CR34","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.ygyno.2019.07.004","volume":"154","author":"LM Ramondetta","year":"2019","unstructured":"Ramondetta LM, Hu W, Thaker PH, Urbauer DL, Chisholm GB, Westin SN, Sun Y, Ramirez PT, Fleming N, Sahai SK, Nick AM, Arevalo JMG, Dizon T, Coleman RL, Cole SW, Sood AK. Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression. Gynecol Oncol. 2019;154(3):524\u201330.","journal-title":"Gynecol Oncol"},{"issue":"27","key":"2994_CR35","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000001097","volume":"94","author":"PY Chang","year":"2015","unstructured":"Chang PY, Huang WY, Lin CL, Huang TC, Wu YY, Chen JH, Kao CH. Propranolol reduces cancer risk: a population-based cohort study. Medicine (Baltim). 2015;94(27): e1097.","journal-title":"Medicine (Baltim)"},{"issue":"10","key":"2994_CR36","doi-asserted-by":"publisher","first-page":"797","DOI":"10.18632\/oncotarget.343","volume":"2","author":"E Pasquier","year":"2011","unstructured":"Pasquier E, Ciccolini J, Carre M, et al. Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget. 2011;2(10):797\u2013809. https:\/\/doi.org\/10.18632\/oncotarget.343.","journal-title":"Oncotarget"},{"issue":"11","key":"2994_CR37","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1002\/ijc.21723","volume":"118","author":"D Palm","year":"2006","unstructured":"Palm D, Lang K, Niggemann B, et al. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB\/c nude mice is inhibited by beta-blockers. Int J Cancer. 2006;118(11):2744\u20139. https:\/\/doi.org\/10.1002\/ijc.21723.","journal-title":"Int J Cancer"},{"issue":"12","key":"2994_CR38","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1016\/j.jpedsurg.2013.08.022","volume":"48","author":"T Xu","year":"2013","unstructured":"Xu T, Xiao X, Zheng S, et al. Antiangiogenic effect of propranolol on the growth of the neuroblastoma xenografts in nude mice. J Pediatr Surg. 2013;48(12):2460\u20135. https:\/\/doi.org\/10.1016\/j.jpedsurg.2013.08.022.","journal-title":"J Pediatr Surg"},{"issue":"10","key":"2994_CR39","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1158\/1940-6207.CAPR-17-0132","volume":"10","author":"KM Huang","year":"2017","unstructured":"Huang KM, Liang S, Yeung S, Oiyemhonlan E, Cleveland KH, Parsa C, Orlando R, Meyskens FL Jr., Andresen BT, Huang Y. Topically applied carvedilol attenuates solar ultraviolet radiation induced skin carcinogenesis. Cancer Prev Res (Phila). 2017;10(10):598\u2013606.","journal-title":"Cancer Prev Res (Phila)"},{"issue":"6","key":"2994_CR40","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1159\/000337979","volume":"83","author":"ST Kim","year":"2012","unstructured":"Kim ST, Park KH, Oh SC, Seo JH, Kim JS, Shin SW, Kim YH. How does inhibition of the renin\u2013angiotensin system affect the prognosis of advanced gastric cancer patients receiving platinum-based chemotherapy? Oncology. 2012;83(6):354\u201360.","journal-title":"Oncology"},{"key":"2994_CR41","doi-asserted-by":"publisher","first-page":"44841","DOI":"10.1038\/srep44841","volume":"7","author":"J Alizadeh","year":"2017","unstructured":"Alizadeh J, Zeki AA, Mirzaei N, Tewary S, Rezaei Moghadam A, Glogowska A, Nagakannan P, Eftekharpour E, Wiechec E, Gordon JW, Xu FY, Field JT, Yoneda KY, Kenyon NJ, Hashemi M, Hatch GM, Hombach-Klonisch S, Klonisch T, Ghavami S. Mevalonate cascade inhibition by simvastatin induces the intrinsic apoptosis pathway via depletion of isoprenoids in tumor cells. Sci Rep. 2017;7:44841.","journal-title":"Sci Rep"},{"issue":"2","key":"2994_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.44","volume":"4","author":"XF Qi","year":"2013","unstructured":"Qi XF, Zheng L, Lee KJ, Kim DH, Kim CS, Cai DQ, Wu Z, Qin JW, Yu YH, Kim SK. HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway. Cell Death Dis. 2013;4(2): e518.","journal-title":"Cell Death Dis"},{"issue":"8","key":"2994_CR43","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.oraloncology.2013.04.003","volume":"49","author":"M Islam","year":"2013","unstructured":"Islam M, Sharma S, Kumar B, Teknos TN. Atorvastatin inhibits RhoC function and limits head and neck cancer metastasis. Oral Oncol. 2013;49(8):778\u201386.","journal-title":"Oral Oncol"},{"issue":"6","key":"2994_CR44","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/j.1349-7006.2007.00471.x","volume":"98","author":"I Takeda","year":"2007","unstructured":"Takeda I, Maruya S, Shirasaki T, Mizukami H, Takahata T, Myers JN, Kakehata S, Yagihashi S, Shinkawa H. Simvastatin inactivates beta1-integrin and extracellular signal-related kinase signaling and inhibits cell proliferation in head and neck squamous cell carcinoma cells. Cancer Sci. 2007;98(6):890\u20139.","journal-title":"Cancer Sci"},{"issue":"6","key":"2994_CR45","first-page":"620","volume":"34","author":"Y Guoxin","year":"2016","unstructured":"Guoxin Y, Bing F, Ronghai Z, Jian Z, Xiaofeng S, Lei T, Qimin W, Jinhong H, Xufei L, Ying W, Yuan Z, Zongxuan H, Yixiang L, Ning L, Lei C, Zhenggang C. Effects of RhoA silencing on proliferation of tongue squamous cancer cells. Hua Xi Kou Qiang Yi Xue Za Zhi. 2016;34(6):620\u20135.","journal-title":"Hua Xi Kou Qiang Yi Xue Za Zhi"},{"issue":"2","key":"2994_CR46","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1111\/jcmm.14879","volume":"24","author":"SW Huang","year":"2020","unstructured":"Huang SW, Chyuan IT, Shiue C, Yu MC, Hsu YF, Hsu MJ. Lovastatin-mediated MCF-7 cancer cell death involves LKB1-AMPK-p38MAPK-p53-survivin signaling cascade. J Cell Mol Med. 2020;24(2):1822\u201336.","journal-title":"J Cell Mol Med"},{"issue":"11","key":"2994_CR47","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1111\/bph.15763","volume":"179","author":"BX Ren","year":"2022","unstructured":"Ren BX, Li Y, Li HM, Lu T, Wu ZQ, Fu R. The antibiotic drug trimethoprim suppresses tumour growth and metastasis via targeting Snail. Br J Pharmacol. 2022;179(11):2659\u201377.","journal-title":"Br J Pharmacol"},{"issue":"10","key":"2994_CR48","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/s41429-021-00433-2","volume":"74","author":"M Ib\u00e1\u00f1ez de Garayo","year":"2021","unstructured":"Ib\u00e1\u00f1ez de Garayo M, Liu W, Rondeau NC, Damoci CB, Miranda JJL. Rationally repurposed nitroxoline inhibits preclinical models of Epstein-Barr virus-associated lymphoproliferation. J Antibiot (Tokyo). 2021;74(10):763\u20136.","journal-title":"J Antibiot (Tokyo)"},{"issue":"46","key":"2994_CR49","doi-asserted-by":"publisher","first-page":"75954","DOI":"10.18632\/oncotarget.12488","volume":"7","author":"CV Alexander-Savino","year":"2016","unstructured":"Alexander-Savino CV, Hayden MS, Richardson C, Zhao J, Poligone B. Doxycycline is an NF-\u03baB inhibitor that induces apoptotic cell death in malignant T-cells. Oncotarget. 2016;7(46):75954\u201367.","journal-title":"Oncotarget"},{"issue":"1","key":"2994_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12010106","volume":"12","author":"M Ahmed","year":"2019","unstructured":"Ahmed M, Jinks N, Babaei-Jadidi R, Kashfi H, Castellanos-Uribe M, May ST, Mukherjee A, Nateri AS. Repurposing antibacterial AM404 as a potential anticancer drug for targeting colorectal cancer stem-like cells. Cancers (Basel). 2019;12(1): 106.","journal-title":"Cancers (Basel)"},{"issue":"23","key":"2994_CR51","doi-asserted-by":"publisher","first-page":"33919","DOI":"10.18632\/oncotarget.8984","volume":"7","author":"E Labay","year":"2016","unstructured":"Labay E, Mauceri HJ, Efimova EV, Flor AC, Sutton HG, Kron SJ, Weichselbaum RR. Repurposing cephalosporin antibiotics as pro-senescent radiosensitizers. Oncotarget. 2016;7(23):33919\u201333.","journal-title":"Oncotarget"},{"key":"2994_CR52","doi-asserted-by":"crossref","DOI":"10.3332\/ecancer.2015.513","volume":"9","author":"AM Van Nuffel","year":"2015","unstructured":"Van Nuffel AM, Sukhatme V, Pantziarka P, Meheus L, Sukhatme VP, Bouche G. Repurposing drugs in oncology (ReDO)-clarithromycin as an anti-cancer agent. Ecancermedicalscience. 2015;9: 513.","journal-title":"Ecancermedicalscience"},{"issue":"5","key":"2994_CR53","doi-asserted-by":"publisher","first-page":"231","DOI":"10.4155\/ppa-2023-0019","volume":"12","author":"N Villa-Ruano","year":"2023","unstructured":"Villa-Ruano N, Marin-Cevada V, Sanchez-Esgua G, Villafa\u00f1a-Diaz L, Perez-Santos M. Drug repurposing of rimantadine for treatment of cancer. Pharm Patient Anal. 2023;12(5):231\u20136.","journal-title":"Pharm Patient Anal"},{"issue":"20","key":"2994_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012240","volume":"23","author":"M Pereira","year":"2022","unstructured":"Pereira M, Vale N. Repurposing alone and in combination of the antiviral saquinavir with 5-fluorouracil in prostate and lung cancer cells. Int J Mol Sci. 2022;23(20): 12240.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2994_CR55","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3892\/ijo.2023.5576","volume":"63","author":"YS Chang","year":"2023","unstructured":"Chang YS, Gills JJ, Kawabata S, Onozawa M, Della Gatta G, Ferrando AA, Aplan PD, Dennis PA. Inhibition of the NOTCH and mTOR pathways by nelfinavir as a novel treatment for T cell acute lymphoblastic leukemia. Int J Oncol. 2023;63(5):128.","journal-title":"Int J Oncol"},{"key":"2994_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122859","volume":"352","author":"KR Paudel","year":"2024","unstructured":"Paudel KR, Singh M, De Rubis G, Kumbhar P, Mehndiratta S, Kokkinis S, El-Sherkawi T, Gupta G, Singh SK, Malik MZ, Mohammed Y, Oliver BG, Disouza J, Patravale V, Hansbro PM, Dua K. Computational and biological approaches in repurposing ribavirin for lung cancer treatment: unveiling antitumorigenic strategies. Life Sci. 2024;352: 122859.","journal-title":"Life Sci"},{"issue":"9","key":"2994_CR57","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1158\/1535-7163.MCT-19-0572","volume":"19","author":"S Huq","year":"2020","unstructured":"Huq S, Casaos J, Serra R, Peters M, Xia Y, Ding AS, Ehresman J, Kedda JN, Morales M, Gorelick NL, Zhao T, Ishida W, Perdomo-Pantoja A, Cecia A, Ji C, Suk I, Sidransky D, Brait M, Brem H, Skuli N, Tyler B. Repurposing the FDA-approved antiviral drug ribavirin as targeted therapy for nasopharyngeal carcinoma. Mol Cancer Ther. 2020;19(9):1797\u2013808.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"2994_CR58","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.amjms.2017.03.025","volume":"354","author":"X Shen","year":"2017","unstructured":"Shen X, Zhu Y, Xiao Z, Dai X, Liu D, Li L, Xiao B. Antiviral drug ribavirin targets thyroid cancer cells by inhibiting the eIF4E-\u03b2-catenin axis. Am J Med Sci. 2017;354(2):182\u20139.","journal-title":"Am J Med Sci"},{"issue":"3","key":"2994_CR59","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.bbrc.2018.10.124","volume":"506","author":"J Chen","year":"2018","unstructured":"Chen J, Xu X, Chen J. Clinically relevant concentration of anti-viral drug ribavirin selectively targets pediatric osteosarcoma and increases chemosensitivity. Biochem Biophys Res Commun. 2018;506(3):604\u201310.","journal-title":"Biochem Biophys Res Commun"},{"key":"2994_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2023.155038","volume":"253","author":"G De Rubis","year":"2024","unstructured":"De Rubis G, Paudel KR, Yeung S, Agarwal V, Hansbro PM, Oliver BGG, Dua K. Ribavirin attenuates carcinogenesis by downregulating IL-6 and IL-8 in vitro in human lung adenocarcinoma. Pathol Res Pract. 2024;253: 155038.","journal-title":"Pathol Res Pract"},{"issue":"2","key":"2994_CR61","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/cbdd.14237","volume":"102","author":"D Akcora-Yildiz","year":"2023","unstructured":"Akcora-Yildiz D, Gonulkirmaz N, Ozkan T, Beksac M, Sunguroglu A. HIV-1 integrase inhibitor raltegravir promotes DNA damage-induced apoptosis in multiple myeloma. Chem Biol Drug Des. 2023;102(2):262\u201370. https:\/\/doi.org\/10.1111\/cbdd.14237.","journal-title":"Chem Biol Drug Des"},{"key":"2994_CR62","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.canlet.2019.02.050","volume":"451","author":"J Yang","year":"2019","unstructured":"Yang J, Xu WW, Hong P, Ye F, Huang XH, Hu HF, Zhang QH, Yan X, Li B, He QY. Adefovir dipivoxil sensitizes colon cancer cells to vemurafenib by disrupting the KCTD12-CDK1 interaction. Cancer Lett. 2019;451:79\u201391.","journal-title":"Cancer Lett"},{"key":"2994_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.121798","volume":"326","author":"HM Abouelezz","year":"2023","unstructured":"Abouelezz HM, El-Kashef DH, Abdelaziz RR, Nader MA. Tenofovir alone or combined with doxorubicin abrogates DMBA-induced mammary cell carcinoma: an insight into its modulatory impact on oxidative\/Notch\/apoptotic signaling. Life Sci. 2023;326: 121798.","journal-title":"Life Sci"},{"issue":"19","key":"2994_CR64","doi-asserted-by":"publisher","first-page":"3568","DOI":"10.1002\/1878-0261.13303","volume":"16","author":"S Bartoloni","year":"2022","unstructured":"Bartoloni S, Leone S, Pescatori S, Cipolletti M, Acconcia F. The antiviral drug telaprevir induces cell death by reducing FOXA1 expression in estrogen receptor \u03b1 (ER\u03b1)-positive breast cancer cells. Mol Oncol. 2022;16(19):3568\u201384.","journal-title":"Mol Oncol"},{"issue":"1","key":"2994_CR65","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4155\/ppa-2021-0021","volume":"11","author":"M Anaya-Ruiz","year":"2022","unstructured":"Anaya-Ruiz M, Perez-Santos M. Drug repurposing of adapalene for melanoma treatment. Pharm Patient Anal. 2022;11(1):9\u201314.","journal-title":"Pharm Patient Anal"},{"issue":"42","key":"2994_CR66","doi-asserted-by":"publisher","first-page":"7222","DOI":"10.2174\/0929867327666200713190520","volume":"27","author":"M Torralba","year":"2020","unstructured":"Torralba M, Farra R, Maddaloni M, Grassi M, Dapas B, Grassi G. Drugs repurposing in high-grade serous ovarian cancer. Curr Med Chem. 2020;27(42):7222\u201333.","journal-title":"Curr Med Chem"},{"key":"2994_CR67","first-page":"610","volume":"10","author":"P Pantziarka","year":"2016","unstructured":"Pantziarka P, Sukhatme V, Bouche G, Meheus L, Sukhatme VP. Repurposing drugs in oncology (ReDO)-diclofenac as an anti-cancer agent. Ecancermedicalscience. 2016;10:610.","journal-title":"Ecancermedicalscience"},{"issue":"1","key":"2994_CR68","doi-asserted-by":"publisher","first-page":"14357","DOI":"10.1038\/s41598-023-41550-2","volume":"13","author":"H Jamialahmadi","year":"2023","unstructured":"Jamialahmadi H, Nazari SE, TanzadehPanah H, Saburi E, Asgharzadeh F, Khojasteh-Leylakoohi F, Alaei M, Mirahmadi M, Babaei F, Asghari SZ, Mansouri S, Khalili-Tanha G, Maftooh M, Fiuji H, Hassanian SM, Ferns GA, Khazaei M, Avan A. Targeting transforming growth factor beta (TGF-\u03b2) using Pirfenidone, a potential repurposing therapeutic strategy in colorectal cancer. Sci Rep. 2023;13(1):14357.","journal-title":"Sci Rep"},{"issue":"52","key":"2994_CR69","doi-asserted-by":"publisher","first-page":"86374","DOI":"10.18632\/oncotarget.13413","volume":"7","author":"M He","year":"2016","unstructured":"He M, Wang D, Zou D, Wang C, Lopes-Bastos B, Jiang WG, Chester J, Zhou Q, Cai J. Re-purposing of curcumin as an anti-metastatic agent for the treatment of epithelial ovarian cancer: in vitro model using cancer stem cell enriched ovarian cancer spheroids. Oncotarget. 2016;7(52):86374\u201387.","journal-title":"Oncotarget"},{"issue":"10","key":"2994_CR70","doi-asserted-by":"publisher","first-page":"3580","DOI":"10.1016\/j.ymthe.2024.08.027","volume":"32","author":"ZK Chen","year":"2024","unstructured":"Chen ZK, Zheng S, Long Y, Wang KM, Xiao BL, Li JB, Zhang W, Song H, Chen G. High-throughput screening identifies ibuprofen as an sEV PD-L1 inhibitor for synergistic cancer immunotherapy. Mol Ther. 2024;32(10):3580\u201396.","journal-title":"Mol Ther"},{"issue":"4","key":"2994_CR71","first-page":"318","volume":"22","author":"Q Ye","year":"2024","unstructured":"Ye Q, Zhu Y, Shi M, Lv L, Gong Y, Zhang L, Yang L, Zhao H, Zhao C, Xu H. Repurposing diacerein to suppress colorectal cancer growth by inhibiting the DCLK1\/STAT3 signaling pathway. Chin J Nat Med. 2024;22(4):318\u201328.","journal-title":"Chin J Nat Med"},{"issue":"24","key":"2994_CR72","doi-asserted-by":"publisher","first-page":"13284","DOI":"10.3390\/ijms222413284","volume":"22","author":"S Md","year":"2021","unstructured":"Md S, Alhakamy NA, Alharbi WS, Ahmad J, Shaik RA, Ibrahim IM, Ali J. Development and evaluation of repurposed etoricoxib loaded nanoemulsion for improving anticancer activities against lung cancer cells. Int J Mol Sci. 2021;22(24):13284.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2994_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109957","volume":"37","author":"J Bi","year":"2021","unstructured":"Bi J, Khan A, Tang J, Armando AM, Wu S, Zhang W, Gimple RC, Reed A, Jing H, Koga T, Wong IT, Gu Y, Miki S, Yang H, Prager B, Curtis EJ, Wainwright DA, Furnari FB, Rich JN, Cloughesy TF, Kornblum HI, Quehenberger O, Rzhetsky A, Cravatt BF, Mischel PS. Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug. Cell Rep. 2021;37(5): 109957.","journal-title":"Cell Rep"},{"issue":"1","key":"2994_CR74","doi-asserted-by":"publisher","first-page":"6050","DOI":"10.1038\/s41598-024-56431-5","volume":"14","author":"C Zhu","year":"2024","unstructured":"Zhu C, Lu Y, Wang S, Song J, Ding Y, Wang Y, Dong C, Liu J, Qiu W, Qi W. Nortriptyline hydrochloride, a potential candidate for drug repurposing, inhibits gastric cancer by inducing oxidative stress by triggering the Keap1-Nrf2 pathway. Sci Rep. 2024;14(1):6050.","journal-title":"Sci Rep"},{"issue":"24","key":"2994_CR75","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202300282","volume":"18","author":"D Chen","year":"2023","unstructured":"Chen D, Chen S, Zhou F, Bo Chen L, Chen MW. Synergistic effects of tranylcypromine and NRF2 inhibitor: a repurposing strategy for effective cancer therapy. ChemMedChem. 2023;18(24): e202300282.","journal-title":"ChemMedChem"},{"issue":"23","key":"2994_CR76","doi-asserted-by":"publisher","first-page":"37511","DOI":"10.18632\/oncotarget.16400","volume":"8","author":"Y Wang","year":"2017","unstructured":"Wang Y, Huang N, Li H, Liu S, Chen X, Yu S, Wu N, Bian XW, Shen HY, Li C, Xiao L. Promoting oligodendroglial-oriented differentiation of glioma stem cell: a repurposing of quetiapine for the treatment of malignant glioma. Oncotarget. 2017;8(23):37511\u201324.","journal-title":"Oncotarget"},{"issue":"1","key":"2994_CR77","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41420-023-01447-5","volume":"9","author":"H Zhang","year":"2023","unstructured":"Zhang H, Han J, Zhang J, Miao J, Li F, Tang K, Zhou K, Duan B, Li W, Cheng J, Sun Y, Hou N, Huang C. Venlafaxine antagonizes the noradrenaline-promoted colon cancer progression by inhibiting the norepinephrine transporter. Cell Death Discov. 2023;9(1):152.","journal-title":"Cell Death Discov"},{"issue":"1","key":"2994_CR78","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1158\/1535-7163.MCT-20-0480","volume":"20","author":"SL Geeraerts","year":"2021","unstructured":"Geeraerts SL, Kampen KR, Rinaldi G, Gupta P, Planque M, Louros N, Heylen E, De Cremer K, De Brucker K, Vereecke S, Verbelen B, Vermeersch P, Schymkowitz J, Rousseau F, Cassiman D, Fendt SM, Voet A, Cammue BPA, Thevissen K, De Keersmaecker K. Repurposing the antidepressant sertraline as SHMT inhibitor to suppress serine\/glycine synthesis-addicted breast tumor growth. Mol Cancer Ther. 2021;20(1):50\u201363.","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"2994_CR79","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.98921","volume":"3","author":"X Jiang","year":"2018","unstructured":"Jiang X, Lu W, Shen X, Wang Q, Lv J, Liu M, Cheng F, Zhao Z, Pang X. Repurposing sertraline sensitizes non-small cell lung cancer cells to erlotinib by inducing autophagy. JCI Insights. 2018;3(11): e98921.","journal-title":"JCI Insights"},{"issue":"11","key":"2994_CR80","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.1007\/s11010-021-04230-1","volume":"476","author":"N Kumar","year":"2021","unstructured":"Kumar N, Raza M, Sehrawat S. Intuitive repositioning of an anti-depressant drug in combination with tivozanib: precision medicine for breast cancer therapy. Mol Cell Biochem. 2021;476(11):4177\u201389.","journal-title":"Mol Cell Biochem"},{"key":"2994_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215717","volume":"540","author":"S Timilsina","year":"2022","unstructured":"Timilsina S, Rajamanickam S, Rao A, Subbarayalu P, Nirzhor S, Abdelfattah N, Viswanadhapalli S, Chen Y, Jatoi I, Brenner A, Rao MK, Vadlamudi R, Kaklamani V. The antidepressant imipramine inhibits breast cancer growth by targeting estrogen receptor signaling and DNA repair events. Cancer Lett. 2022;540: 215717.","journal-title":"Cancer Lett"},{"issue":"9","key":"2994_CR82","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.21873\/anticanres.16586","volume":"43","author":"LC Hsu","year":"2023","unstructured":"Hsu LC, Lin CN, Hsu FT, Chen YT, Chang PL, Hsieh LL, Wang HY, Lin KH, Hsiao HC, Tu HF. Imipramine suppresses tumor growth and induces apoptosis in oral squamous cell carcinoma: targeting multiple processes and signaling pathways. Anticancer Res. 2023;43(9):3987\u201396.","journal-title":"Anticancer Res"},{"key":"2994_CR83","doi-asserted-by":"crossref","unstructured":"Fayyaz S, Atia-Tul-Wahab, Irshad R, Siddiqui RA, Choudhary MI. Antidepressant sertraline hydrochloride inhibits the growth of HER2+ AU565 breast cancer cell line through induction of apoptosis and cell cycle arrest. Anticancer Agents Med Chem. 2024;24(14):1038\u201346.","DOI":"10.2174\/0118715206304918240509111700"},{"key":"2994_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2021.127997","volume":"41","author":"C Mu","year":"2021","unstructured":"Mu C, Peng RK, Guo CL, Li A, Yang XM, Zeng R, Li YL, Gu J, Ouyang Q. Discovery of sertraline and its derivatives able to combat drug-resistant gastric cancer cell via inducing apoptosis. Bioorg Med Chem Lett. 2021;41: 127997.","journal-title":"Bioorg Med Chem Lett"},{"issue":"12","key":"2994_CR85","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1080\/14728222.2022.2166829","volume":"26","author":"C Chomchoei","year":"2022","unstructured":"Chomchoei C, Brimson JM, Brimson S. Repurposing fluoxetine to treat lymphocytic leukemia: apoptosis induction, sigma-1 receptor upregulation, inhibition of IL-2 cytokine production, and autophagy induction. Expert Opin Ther Targets. 2022;26(12):1087\u201397.","journal-title":"Expert Opin Ther Targets"},{"key":"2994_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.689767","volume":"12","author":"C Zheng","year":"2021","unstructured":"Zheng C, Zhu Y, Liu Q, Luo T, Xu W. Maprotiline suppresses cholesterol biosynthesis and hepatocellular carcinoma progression through direct targeting of CRABP1. Front Pharmacol. 2021;12: 689767.","journal-title":"Front Pharmacol"},{"issue":"14","key":"2994_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2020.127239","volume":"30","author":"Y Chen","year":"2020","unstructured":"Chen Y, Cui Y, Sun X, Wu H, Ou M, Tang Y, Ni S, Li X, Zhu J, Mao F, Wang Y, Li J. Repurposing of antipsychotics perphenazine for the treatment of endometrial cancer. Bioorg Med Chem Lett. 2020;30(14): 127239.","journal-title":"Bioorg Med Chem Lett"},{"key":"2994_CR88","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.omto.2020.08.019","volume":"19","author":"S Ramachandran","year":"2020","unstructured":"Ramachandran S, Srivastava SK. Repurposing pimavanserin, an anti-Parkinson drug for pancreatic cancer therapy. Mol Ther Oncolytics. 2020;19:19\u201332.","journal-title":"Mol Ther Oncolytics"},{"issue":"9","key":"2994_CR89","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091310","volume":"11","author":"H Kim","year":"2019","unstructured":"Kim H, Chong K, Ryu BK, Park KJ, Yu MO, Lee J, Chung S, Choi S, Park MJ, Chung YG, Kang SH. Repurposing penfluridol in combination with temozolomide for the treatment of glioblastoma. Cancers (Basel). 2019;11(9): 1310.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2994_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-019-0186-3","volume":"9","author":"S Bibbo","year":"2020","unstructured":"Bibbo S, Lamolinara A, Capone E, Purgato S, Tsakaneli A, Panella V, Sallese M, Rossi C, Ciufici P, Nieddu V, De Laurenzi V, Iezzi M, Perini G, Sala G, Sala A. Repurposing a psychoactive drug for children with cancer: p27Kip1-dependent inhibition of metastatic neuroblastomas by Prozac. Oncogenesis. 2020;9(1): 3.","journal-title":"Oncogenesis"},{"issue":"1","key":"2994_CR91","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12964-023-01190-5","volume":"21","author":"TH Tran","year":"2023","unstructured":"Tran TH, Kao M, Liu HS, Hong YR, Su Y, Huang CF. Repurposing thioridazine for inducing immunogenic cell death in colorectal cancer via eIF2\u03b1\/ATF4\/CHOP and secretory autophagy pathways. Cell Commun Signal. 2023;21(1):184.","journal-title":"Cell Commun Signal"},{"key":"2994_CR92","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.3389\/fphar.2019.01029","volume":"10","author":"Y Xia","year":"2019","unstructured":"Xia Y, Jia C, Xue Q, Jiang J, Xie Y, Wang R, Ran Z, Xu F, Zhang Y, Ye T. Antipsychotic drug trifluoperazine suppresses colorectal cancer by inducing G0\/G1 arrest and apoptosis. Front Pharmacol. 2019;10:1029.","journal-title":"Front Pharmacol"},{"issue":"2","key":"2994_CR93","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.3802\/jgo.2025.36.e28","volume":"36","author":"WJ Kim","year":"2024","unstructured":"Kim WJ, Ryu JY, Chang CS, Cho YJ, Choi JJ, Hwang JR, Choi JY, Lee JW. Anticancer effect of the antipsychotic agent penfluridol on epithelial ovarian cancer. J Gynecol Oncol. 2024;36(2):e28.","journal-title":"J Gynecol Oncol"},{"issue":"4","key":"2994_CR94","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41419-022-04828-3","volume":"13","author":"MC Tung","year":"2022","unstructured":"Tung MC, Lin YW, Lee WJ, Wen YC, Liu YC, Chen JQ, Hsiao M, Yang YC, Chien MH. Targeting DRD2 by the antipsychotic drug, penfluridol, retards growth of renal cell carcinoma via inducing stemness inhibition and autophagy-mediated apoptosis. Cell Death Dis. 2022;13(4):400.","journal-title":"Cell Death Dis"},{"key":"2994_CR95","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.635472","volume":"11","author":"S Matteoni","year":"2021","unstructured":"Matteoni S, Matarrese P, Ascione B, Buccarelli M, Ricci-Vitiani L, Pallini R, Villani V, Pace A, Paggi MG, Abbruzzese C. Anticancer properties of the antipsychotic drug chlorpromazine and its synergism with temozolomide in restraining human glioblastoma proliferation in vitro. Front Oncol. 2021;11: 635472.","journal-title":"Front Oncol"},{"issue":"14","key":"2994_CR96","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411852","volume":"24","author":"CY Hsu","year":"2023","unstructured":"Hsu CY, Yang WT, Lin JH, Lu CH, Hu KC, Lan TH, Chang CC. Sertindole, an antipsychotic drug, curbs the STAT3\/BCL-xL axis to elicit human bladder cancer cell apoptosis in vitro. Int J Mol Sci. 2023;24(14): 11852.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2994_CR97","first-page":"459","volume":"9","author":"F Xu","year":"2019","unstructured":"Xu F, Xia Y, Feng Z, Lin W, Xue Q, Jiang J, Yu X, Peng C, Luo M, Yang Y, Wei Y, Yu L. Repositioning antipsychotic fluphenazine hydrochloride for treating triple negative breast cancer with brain metastases and lung metastases. Am J Cancer Res. 2019;9(3):459\u201378.","journal-title":"Am J Cancer Res"},{"issue":"2","key":"2994_CR98","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/hed.27238","volume":"45","author":"CF Yeh","year":"2023","unstructured":"Yeh CF, Lee WY, Yu TH, Hsu YB, Lan MC, Lan MY. Antipsychotic drug trifluoperazine as a potential therapeutic agent against nasopharyngeal carcinoma. Head Neck. 2023;45(2):316\u201328.","journal-title":"Head Neck"},{"issue":"8","key":"2994_CR99","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0235676","volume":"15","author":"A Badran","year":"2020","unstructured":"Badran A, Tul-Wahab A, Zafar H, Mohammad N, Imad R, Ashfaq Khan M, Baydoun E, Choudhary MI. Antipsychotics drug aripiprazole as a lead against breast cancer cell line (MCF-7) in vitro. PLoS ONE. 2020;15(8): e0235676.","journal-title":"PLoS ONE"},{"issue":"3","key":"2994_CR100","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00280-021-04386-z","volume":"89","author":"F Xu","year":"2022","unstructured":"Xu F, Xi H, Liao M, Zhang Y, Ma H, Wu M, Xue Q, Sun H, Zhang Y, Xia Y. Repurposed antipsychotic chlorpromazine inhibits colorectal cancer and pulmonary metastasis by inducing G2\/M cell cycle arrest, apoptosis, and autophagy. Cancer Chemother Pharmacol. 2022;89(3):331\u201346.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"2994_CR101","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41\u201358. https:\/\/doi.org\/10.1038\/nrd.2018.168.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"2994_CR102","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.tips.2021.01.003","volume":"42","author":"HI Roessler","year":"2021","unstructured":"Roessler HI, Knoers NVAM, van Haelst MM, van Haaften G. Drug repurposing for rare diseases. Trends Pharmacol Sci. 2021;42(4):255\u201367. https:\/\/doi.org\/10.1016\/j.tips.2021.01.003.","journal-title":"Trends Pharmacol Sci"},{"issue":"7","key":"2994_CR103","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2147\/DDDT.S46289","volume":"2013","author":"M Allarakhia","year":"2013","unstructured":"Allarakhia M. Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases. Drug Des Dev Ther. 2013;2013(7):753\u201366. https:\/\/doi.org\/10.2147\/DDDT.S46289.","journal-title":"Drug Des Dev Ther"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02994-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02994-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02994-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T08:02:17Z","timestamp":1758096137000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02994-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,24]]},"references-count":103,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["2994"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02994-w","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,24]]},"assertion":[{"value":"28 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"443"}}